Abstract Background and Aims Children undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) are particularly vulnerable to acute kidney injury (AKI), especially in the early post-transplantation period. The major risk factors of AKI development aggressive immunosuppression infectious complications. In meantime, malnutrition hypermetabolic state patient, together with routine ...

BACKGROUND Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences. Here we report 20 years experience of HSCT. OBJECTIVES Our strategy and aim include the protr...

Unrelated haematopoietic stem cell transplantation (HSCT) has evolved from an experimental protocol to a potentially curative first-line treatment in variety of haematologic malignancies. The continuous refinement protocols and supportive care paired with ongoing achievements the technological field histocompatibility testing enabled this transformation. Without doubt, HLA matching is still for...

OBJECTIVE To review the available clinical data on the critical care complications of hematopoietic stem cell transplantation (HSCT). DATA SOURCE The MEDLINE database and references from the identified articles related to the critical care in HSCT. CONCLUSION HSCT is an important treatment for a variety of malignant and nonmalignant conditions. The procedure is, however, limited by signific...

Delayed recovery of platelet count post allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been associated with worse transplant outcomes. Thrombopoietic agents have been successfully used in immune mediated thrombocytopenia or thrombocytopenia from bone marrow failure syndromes; however, the experience regarding their use after allo-HSCT is limited. Here we report on the safety...

BACKGROUND AND OBJECTIVES Intensive chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) is a curative treatment option for patients with myelodysplastic syndromes (MDS). Peripheral blood (PB) HSCT was introduced in 1992 and PB has become the source of choice of autologous stem cells worldwide. Autologous PB stem cells result in faster hematopoietic recovery, but m...

2. Narrative: In the Phase I grant application, we hypothesized that the hematopoietic stem cell therapy (HSCT) could prevent/mitigate astronauts' various disorders in space, enabling them to “go anywhere at anytime” and come back to earth just as they left. Amongst the disorders in space, which include hematological/cardiac abnormalities, bone and muscle losses, immunodeficiency, neurological ...

BACKGROUND Dyskeratosis congenita (DC) is a progressive, multi-system, inherited disorder of telomere biology with high risks of morbidity and mortality from bone marrow failure, hematologic malignancy, solid tumors and pulmonary fibrosis. Hematopoietic stem cell transplantation (HSCT) can cure the bone marrow failure, but it does not eliminate the risks of other complications, for which life-l...

BACKGROUND Travel activity and travel-related risks of patients after allogeneic haematopoietic stem cell transplantation (allo-HSCT) remain largely unknown. The aim of our study was to examine travel activity after allo-HSCT including travel behaviour and travel patterns. METHODS We analysed travel characteristics of allo-HSCT recipients by using a retrospective cross-sectional survey. Allo-...

Abstract Background This prospective longitudinal study examined and compared two measures (prospective retrospective ones) of post-traumatic growth (PTG) following Hematopoietic Stem-Cell Transplantation (HSCT) their respective relationships with mental health psychological disposition. We also tested the hypothesis that unwillingness to be in contact distressing thoughts feelings—i.e. experie...